Astra acquiring Fisons R&D programs in non-respiratory areas for $321 mil.
ASTRA ACQUIRING FISONS R&D PROGRAMS IN NON-RESPIRATORY AREAS for [pound]202 mil. ($321.2 mil.), the companies announced March 17. The agreement in principle calls for Astra AB to acquire Fisons' U.K. research facilities in Loughborough and its R&D operations from Rochester, N.Y. Astra is not acquiring any U.S. facilities from Fisons. Astra will add approximately 900 Fisons research employees from the two sites; 200 will remain with Fisons.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth